Drug Trial Radar · NCT00026143
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
Last checked: Nov 20, 2026Latest source record: Jun 5, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Oct 2001
Primary completion
Jul 2004
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II trial to study the effectiveness of combining interleukin-12 and interferon alfa in treating patients who have metastatic malignant melanoma. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Interferon alfa may interfere with the growth of the cancer cells. Combining interleukin-12 and interferon alfa may kill more tumor cells.
Conditions
- Recurrent Melanoma
- Stage IV Melanoma
Interventions
recombinant interleukin-12Biological
Given IV
recombinant interferon alfaBiological
Given SC
laboratory biomarker analysisOther
Correlative studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response rateTime frame: Up to 2 years
- PFSTime frame: From registration until time of documented progression of disease or death from any cause, assessed up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer and Leukemia Group B
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.